Elutia Announces $13.26 Million Registered Direct Offering
June 17, 2024 08:01 ET
|
Elutia Inc.
SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the...
Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
June 17, 2024 08:00 ET
|
Elutia Inc.
EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for...
Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024
May 13, 2024 08:00 ET
|
Elutia Inc.
SILVER SPRING, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, is excited to announce its participation in the...
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance
May 09, 2024 16:05 ET
|
Elutia Inc.
SILVER SPRING, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a company pioneering drug-eluting biomatrix products, today provided a business update...
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
May 02, 2024 16:05 ET
|
Elutia Inc.
SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its first...
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
April 24, 2024 16:05 ET
|
Elutia Inc.
SILVER SPRING, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President...
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
March 07, 2024 16:05 ET
|
Elutia Inc.
SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter...
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
February 22, 2024 16:05 ET
|
Elutia Inc.
SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth...
Elutia Regains Compliance with Nasdaq Listing Requirements
January 10, 2024 16:05 ET
|
Elutia Inc.
SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq’s market value of listed securities requirement and...
Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance
December 18, 2023 08:00 ET
|
Elutia Inc.
510(k) filing follows FDA feedback from successful pre-submission meeting SILVER SPRING, Md., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced it has submitted a 510(k)...